TY - JOUR
KW - Substance Use Disorders -- Therapy -- In Pregnancy
KW - Treatment Outcomes
KW - outcome assessment
KW - Disease Surveillance
KW - Maternal-child health
KW - Pregnancy
KW - Female
KW - Narcotics -- Adverse Effects
KW - Pregnancy Outcomes
KW - Narcotic Antagonists -- Therapeutic Use
KW - Methadone -- therapeutic use
KW - buprenorphine
KW - Behavior Therapy
KW - Medicine, Herbal
AU - Emmy L. Tran
AU - Shin Y. Kim
AU - Lucinda J. England
AU - Caitlin Green
AU - Elizabeth P. Dang
AU - Cheryl S. Broussard
AU - Nicole Fehrenbach
AU - Amy Hudson
AU - Tineka Yowe-Conley
AU - Suzanne M. Gilboa
AU - Dana Meaney-Delman
A1 - 
AD - Eagle Global Scientific LLC, San Antonio, Texas, USA.; Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
BT - Journal of Women's Health (15409996)
C5 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
CP - 12
CY - New Rochelle, New York
DO - 10.1089/jwh.2020.8848
IS - 12
JF - Journal of Women's Health (15409996)
LA - English
M1 - Journal Article
PB - Mary Ann Liebert, Inc
PP - New Rochelle, New York
PY - 2020
SN - 1540-9996
SP - 1491
EP - 1499
EP - 
T1 - The MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment of Opioid Use Disorder During Pregnancy (MAT-LINK): Surveillance Opportunity
T2 - Journal of Women's Health (15409996)
TI - The MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment of Opioid Use Disorder During Pregnancy (MAT-LINK): Surveillance Opportunity
U1 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U3 - 10.1089/jwh.2020.8848
VL - 29
VO - 1540-9996
Y1 - 2020
Y2 - 12
ER -